Tests a heart care plan for COVID-19 survivors at risk of heart failure
Tests a heart care plan in COVID-19 survivors over 50 with reduced fitness.
Plain-language title generated from the registry record
Registry title: Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
Key facts
- Where
- Melbourne, AustraliaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 to 85 who have had COVID-19 and live close enough to attend follow-up. It tests ways to protect the heart and prevent heart failure.
- Age
- 50 Years to 85 Years
- Sex
- All sexes can join.
- Disease stage
- History of COVID-19 infection. People with earlier heart failure (NYHA class above 2) cannot join.
- Earlier treatment
- People already taking both an ACE inhibitor or angiotensin receptor blocker and a beta blocker cannot join.
Main reasons for not taking part
- Valvular stenosis or regurgitation worse than moderate
- Previous heart failure (NYHA class above 2)
- Contraindications to beta blockers or angiotensin-converting enzyme inhibitors
- Life expectancy under 12 months or pregnancy
- Mobility problem that would limit exercise
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT04983823, who can take part
Where in Australia
- Baker Heart and Diabetes InstituteMelbourne, AustraliaContact: Thomas MarwickTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Baker Heart and Diabetes Institute
- Trial code
- NCT04983823
- Record updated
- 3 October 2025
- Original description
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors >50 years old.Read full original descriptionShow less
Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors >50 years old.
The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.
Inclusion: History of COVID-19 infection; Live within a geographically accessible area for follow-up.
Exclusion: History of previous heart failure (baseline New York Heart Association (NYHA) classification >2); Contraindications to beta blockers or angiotensin-converting enzyme inhibitors; Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial; Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both; Mobility impairment that would impact participants' ability to perform exercise; Valvular stenosis or regurgitation of >moderate severity; Inability to acquire interpretable images (identified from baseline echo); Unable to provide written informed consent to participate in this study.